Is GOVX or SNTI more profitable?

GeoVax Labs' return on equity of -743.64% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Senti Biosciences N/A -1,629.80% -119.72%

Does the media prefer GOVX or SNTI?

In the previous week, GeoVax Labs and GeoVax Labs both had 1 articles in the media. Senti Biosciences' average media sentiment score of 0.97 beat GeoVax Labs' score of 0.84 indicating that Senti Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GOVX or APRE more profitable?

Aprea Therapeutics' return on equity of -47.60% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Aprea Therapeutics N/A -47.60% -40.97%

Do analysts recommend GOVX or IMRN?

GeoVax Labs currently has a consensus target price of $150.00, suggesting a potential upside of 46,053.85%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe GeoVax Labs is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, GOVX or IMRN?

Immuron has higher revenue and earnings than GeoVax Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs $2.49M 0.96 -$21.47M -$11.34 N/A Immuron $5.47M 1.61 -$2.50M N/A N/A

Is GOVX or IMRN more profitable?

Immuron's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Immuron N/A N/A N/A

Does the media refer more to GOVX or IMRN?

In the previous week, GeoVax Labs and GeoVax Labs both had 1 articles in the media. GeoVax Labs' average media sentiment score of 0.84 beat Immuron's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GOVX or FBLG more profitable?

FibroBiologics' return on equity of -536.78% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% FibroBiologics N/A -536.78% -225.12%

Does the media refer more to GOVX or FBLG?

In the previous week, FibroBiologics had 2 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.84 beat FibroBiologics' score of 0.21 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GOVX or KALA?

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 46,053.85%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe GeoVax Labs is more favorable than KALA BIO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 KALA BIO 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, GOVX or KALA?

GeoVax Labs has higher revenue and earnings than KALA BIO. GeoVax Labs is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs $2.49M 0.96 -$21.47M -$11.34 N/A KALA BIO N/A N/A -$26.98M -$31.96 N/A

Is GOVX or KALA more profitable?

KALA BIO's return on equity of -222.35% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% KALA BIO N/A -222.35% -70.23%

Does the media refer more to GOVX or KALA?

In the previous week, GeoVax Labs and GeoVax Labs both had 1 articles in the media. GeoVax Labs' average media sentiment score of 0.84 beat KALA BIO's score of 0.12 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GeoVax Labs (GOVX) Competitors

$0.32 0.00 (-0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$0.31 -0.01 (-1.91%)

As of 05:58 PM Eastern

Compare

GOVX vs. SNTI, APRE, IMRN, FBLG, and KALA

Should you buy GeoVax Labs stock or one of its competitors? GeoVax Labs's main competitors and comparable companies include Senti Biosciences (SNTI), Aprea Therapeutics (APRE), Immuron (IMRN), FibroBiologics (FBLG), and KALA BIO (KALA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GeoVax Labs compare to Senti Biosciences?

GeoVax Labs (NASDAQ:GOVX) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

GeoVax Labs has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.96	-$21.47M	-$11.34	N/A
Senti Biosciences	$20K	506.19	-$61.44M	-$1.77	N/A

GeoVax Labs' return on equity of -743.64% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Senti Biosciences	N/A	-1,629.80%	-119.72%

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 46,053.85%. Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 2,976.92%. Given GeoVax Labs' higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Senti Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

GeoVax Labs has a beta of 3.69, meaning that its share price is 269% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, GeoVax Labs and GeoVax Labs both had 1 articles in the media. Senti Biosciences' average media sentiment score of 0.97 beat GeoVax Labs' score of 0.84 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Senti Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Senti Biosciences beats GeoVax Labs on 9 of the 15 factors compared between the two stocks.

How does GeoVax Labs compare to Aprea Therapeutics?

GeoVax Labs (NASDAQ:GOVX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

GeoVax Labs presently has a consensus target price of $150.00, indicating a potential upside of 46,053.85%. Aprea Therapeutics has a consensus target price of $3.07, indicating a potential upside of 331.92%. Given GeoVax Labs' higher probable upside, research analysts clearly believe GeoVax Labs is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

GeoVax Labs has a beta of 3.69, indicating that its share price is 269% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

Aprea Therapeutics' return on equity of -47.60% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Aprea Therapeutics	N/A	-47.60%	-40.97%

Aprea Therapeutics has lower revenue, but higher earnings than GeoVax Labs. Aprea Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.96	-$21.47M	-$11.34	N/A
Aprea Therapeutics	$290K	30.82	-$12.60M	-$1.08	N/A

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, GeoVax Labs had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 1 mentions for GeoVax Labs and 0 mentions for Aprea Therapeutics. GeoVax Labs' average media sentiment score of 0.84 beat Aprea Therapeutics' score of -0.66 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Positive
Aprea Therapeutics	Negative

Summary

Aprea Therapeutics beats GeoVax Labs on 9 of the 15 factors compared between the two stocks.

How does GeoVax Labs compare to Immuron?

GeoVax Labs (NASDAQ:GOVX) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

GeoVax Labs currently has a consensus target price of $150.00, suggesting a potential upside of 46,053.85%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe GeoVax Labs is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GeoVax Labs has a beta of 3.69, indicating that its share price is 269% more volatile than the broader market. Comparatively, Immuron has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Immuron's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Immuron	N/A	N/A	N/A

Immuron has higher revenue and earnings than GeoVax Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.96	-$21.47M	-$11.34	N/A
Immuron	$5.47M	1.61	-$2.50M	N/A	N/A

In the previous week, GeoVax Labs and GeoVax Labs both had 1 articles in the media. GeoVax Labs' average media sentiment score of 0.84 beat Immuron's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by company insiders. Comparatively, 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

GeoVax Labs and Immuron tied by winning 6 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to FibroBiologics?

GeoVax Labs (NASDAQ:GOVX) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

GeoVax Labs has a beta of 3.69, suggesting that its share price is 269% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 46,053.85%. FibroBiologics has a consensus price target of $73.00, indicating a potential upside of 6,220.35%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities research analysts clearly believe GeoVax Labs is more favorable than FibroBiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

6.1% of GeoVax Labs shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by company insiders. Comparatively, 7.3% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

FibroBiologics has lower revenue, but higher earnings than GeoVax Labs. FibroBiologics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.96	-$21.47M	-$11.34	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

In the previous week, FibroBiologics had 2 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.84 beat FibroBiologics' score of 0.21 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

FibroBiologics' return on equity of -536.78% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
FibroBiologics	N/A	-536.78%	-225.12%

Summary

GeoVax Labs beats FibroBiologics on 7 of the 13 factors compared between the two stocks.

How does GeoVax Labs compare to KALA BIO?

GeoVax Labs (NASDAQ:GOVX) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, GeoVax Labs and GeoVax Labs both had 1 articles in the media. GeoVax Labs' average media sentiment score of 0.84 beat KALA BIO's score of 0.12 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeoVax Labs has higher revenue and earnings than KALA BIO. GeoVax Labs is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.96	-$21.47M	-$11.34	N/A
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A

KALA BIO's return on equity of -222.35% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
KALA BIO	N/A	-222.35%	-70.23%

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GeoVax Labs has a beta of 3.69, indicating that its stock price is 269% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.39, indicating that its stock price is 339% less volatile than the broader market.

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 46,053.85%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe GeoVax Labs is more favorable than KALA BIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
KALA BIO	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

GeoVax Labs beats KALA BIO on 8 of the 13 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOVX vs. The Competition

Export

Metric	GeoVax Labs	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.36M	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-0.03	12.99	274.61	26.05
Price / Sales	0.95	1,288.54	601.02	89.39
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	0.14	16.63	10.92	6.31
Net Income	-$21.47M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-8.80%	-3.06%	-2.11%	-1.67%
1 Month Performance	-42.06%	-10.76%	-6.34%	-3.94%
1 Year Performance	-97.69%	21.10%	8.81%	2.77%

GeoVax Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOVX GeoVax Labs	2.7046 of 5 stars	$0.32 -0.7%	$150.00 +46,760.4%	-97.6%	$2.36M	$2.49M	N/A	19
SNTI Senti Biosciences	3.2531 of 5 stars	$0.31 -5.9%	$10.00 +3,125.8%	-77.5%	$10.26M	$20K	N/A	39	Positive News Gap Down
APRE Aprea Therapeutics	2.8684 of 5 stars	$0.75 -1.2%	$3.07 +307.9%	-50.4%	$9.58M	$290K	N/A	8
IMRN Immuron	0.1575 of 5 stars	$1.16 flat	N/A	-40.8%	$9.36M	$5.47M	N/A	7
FBLG FibroBiologics	2.0053 of 5 stars	$1.36 -2.2%	$73.00 +5,267.6%	-88.5%	$9.25M	N/A	N/A	15	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOVX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeoVax Labs (GOVX) Competitors

GOVX vs. SNTI, APRE, IMRN, FBLG, and KALA

How does GeoVax Labs compare to Senti Biosciences?

Summary

How does GeoVax Labs compare to Aprea Therapeutics?

Summary

How does GeoVax Labs compare to Immuron?

Summary

How does GeoVax Labs compare to FibroBiologics?

Summary

How does GeoVax Labs compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeoVax Labs (GOVX) Competitors

GOVX vs. SNTI, APRE, IMRN, FBLG, and KALA

How does GeoVax Labs compare to Senti Biosciences?

Which has stronger earnings & valuation, GOVX or SNTI?

Is GOVX or SNTI more profitable?

Do analysts prefer GOVX or SNTI?

Which has more risk and volatility, GOVX or SNTI?

Do insiders & institutionals have more ownership in GOVX or SNTI?

Does the media prefer GOVX or SNTI?

Summary

How does GeoVax Labs compare to Aprea Therapeutics?

Do analysts prefer GOVX or APRE?

Which has more volatility and risk, GOVX or APRE?

Is GOVX or APRE more profitable?

Which has better earnings & valuation, GOVX or APRE?

Do insiders & institutionals believe in GOVX or APRE?

Does the media prefer GOVX or APRE?

Summary

How does GeoVax Labs compare to Immuron?

Do analysts recommend GOVX or IMRN?

Which has more volatility & risk, GOVX or IMRN?

Is GOVX or IMRN more profitable?

Which has stronger valuation & earnings, GOVX or IMRN?

Does the media refer more to GOVX or IMRN?

Do insiders and institutionals have more ownership in GOVX or IMRN?

Summary

How does GeoVax Labs compare to FibroBiologics?

Which has more volatility and risk, GOVX or FBLG?

Do analysts prefer GOVX or FBLG?

Do institutionals and insiders believe in GOVX or FBLG?

Which has preferable earnings & valuation, GOVX or FBLG?

Does the media refer more to GOVX or FBLG?

Is GOVX or FBLG more profitable?

Summary

How does GeoVax Labs compare to KALA BIO?

Does the media refer more to GOVX or KALA?

Which has better earnings and valuation, GOVX or KALA?

Is GOVX or KALA more profitable?

Do institutionals & insiders have more ownership in GOVX or KALA?

Which has more risk & volatility, GOVX or KALA?

Do analysts rate GOVX or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools